Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Clonal hematopoiesis and atherosclerosis

Expansion of fibroblast-like cells may explain the CANTOS meta-analysis findings for patients with clonal hematopoiesis

Nature Cardiovascular Research volume 3, pages 23–25 (2024)Cite this article

Subjects

Clonal hematopoiesis of indeterminate potential (CHIP) is a risk factor for cardiovascular disease. Neutralization of the cytokine IL-1β (as in the CANTOS clinical trial) resulted in a greater reduction in adverse cardiovascular events in patients with CHIP than the reduction in molecularly unstratified patients. New research reveals that some of the cardiovascular benefits of anti-IL-1β therapy in patients with CHIP might be delivered by an improvement in plaque stability via increased fibroblast-like cells.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Neutralization of IL-1β expands fibroblast-like cell populations in atherosclerosis combined with clonal hematopoiesis.

References

  1. Jaiswal, S. et al. N. Engl. J. Med. 377, 111–121 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  2. Fuster, J. J. et al. Science 355, 842–847 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Fidler, T. P. et al. Nature 592, 296–301 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Ridker, P. M. et al. N. Engl. J. Med. 377, 1119–1131 (2017).

    Article  CAS  PubMed  Google Scholar 

  5. Svensson, E. C. et al. JAMA Cardiol. 7, 521–528 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  6. Fidler, T. P. et al. Nat. Cardiovasc. Res. https://doi.org/10.1038/s44161-023-00405-9 (2023).

    Article  Google Scholar 

  7. Gomez, D. et al. Nat. Med. 24, 1418–1429 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Li, J. et al. Blood 123, 3139–3151 (2014).

    Article  CAS  PubMed  Google Scholar 

  9. Raber, L. et al. J. Am. Med. Assoc. 327, 1771–1781 (2022).

    Article  CAS  Google Scholar 

  10. Everett, B. M. et al. Circulation 139, 1289–1299 (2019).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The University of Cambridge, Victor Phillip Dahdaleh Heart and Lung Research Institute, Cambridge Biomedical Campus, Cambridge, UK

    Xuan Li & Murray C. H. Clarke

Authors
  1. Xuan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Murray C. H. Clarke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xuan Li.

Ethics declarations

Competing interests

X.L. is an inventor on the UK patent ‘Treatment of Inflammatory Diseases’ (application no. 2313514.8). M.C.H.C. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, X., Clarke, M.C.H. Expansion of fibroblast-like cells may explain the CANTOS meta-analysis findings for patients with clonal hematopoiesis. Nat Cardiovasc Res 3, 23–25 (2024). https://doi.org/10.1038/s44161-023-00409-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s44161-023-00409-5

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing